A multi‐institutional comparison of mitoxantrone, etoposide, and cytarabine vs high‐dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia
Open Access
- 8 May 2020
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 95 (8) , 937-943
Abstract
Relapsed or refractory acute myeloid leukemia (R/R AML) has a poor prognosis and is best treated with salvage chemotherapy as a bridge to allogeneic stem cell transplant (alloSCT). However, the optimal salvage therapy remains unknown. Here we compared two salvage regimens; mitoxantrone, etoposide, and cytarabine (MEC) and mitoxantrone and high‐dose Ara‐C (Ara‐C couplets). We analyzed 155 patients treated at three academic institutions between 1998 and 2017; 87 patients received MEC and 68 received Ara‐C couplets. The primary endpoint was overall response (OR). Secondary endpoints included progression‐free survival (PFS), overall survival (OS), duration of hospitalization, hematologic and nonhematologic toxicities, and success in proceeding to alloSCT. Baseline characteristics of the cohorts were well matched, though patients receiving Ara‐C couplets had more co‐morbidities (48.5% vs 33%; P = .07). OR was achieved in 43.7% of MEC and 54.4% of Ara‐C couplets patients (P = .10). Ara‐C couplets patients also trended towards a longer OS and PFS, more frequently proceeded to alloSCT (31% vs 54.4%; P = .003), and experienced less febrile neutropenia (94% vs 72%; P < .001) and grade 3/4 gastrointestinal toxicities (17.2% vs 2.94%; P = .005). No significant differences in other toxicities or median duration of hospitalization were noted. This is the first multi‐institutional study directly comparing these regimens in a racially diverse population of R/R AML patients. Although these regimens have equivalent efficacy in terms of achieving OR, Ara‐C couplets use is associated with significant reductions in toxicities, suggesting it should be used more frequently in these patients.Keywords
This publication has 20 references indexed in Scilit:
- Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature reviewAnnals of Hematology, 2018
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- How I treat refractory and early relapsed acute myeloid leukemiaBlood, 2015
- High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)Leukemia & Lymphoma, 2011
- Therapeutic Advances in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Questions regarding frontline therapy of acute myeloid leukemiaCancer, 2010
- Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First RelapseJournal of Clinical Oncology, 2005
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.Journal of Clinical Oncology, 1991
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987